ADCETRIS
Biological
Seagen Inc.
Total Payments
$239.7M
Transactions
63,286
Doctors
11,100
Companies
7
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $13.2M | 2,685 | 948 |
| 2023 | $38.4M | 13,261 | 4,474 |
| 2022 | $38.4M | 12,501 | 3,725 |
| 2021 | $41.0M | 8,031 | 2,654 |
| 2020 | $31.2M | 4,411 | 1,634 |
| 2019 | $22.5M | 7,422 | 2,804 |
| 2018 | $26.9M | 10,065 | 3,834 |
| 2017 | $28.1M | 4,910 | 1,968 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $227.5M | 15,121 | 94.9% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $6.6M | 1,993 | 2.8% |
| Consulting Fee | $2.2M | 495 | 0.9% |
| Travel and Lodging | $1.1M | 2,996 | 0.5% |
| Food and Beverage | $1.1M | 39,794 | 0.4% |
| Space rental or facility fees (teaching hospital only) | $475,126 | 265 | 0.2% |
| Honoraria | $368,679 | 115 | 0.2% |
| Education | $335,245 | 2,484 | 0.1% |
| Grant | $137,544 | 22 | 0.1% |
| Charitable Contribution | $1,000 | 1 | 0.0% |
Payments by Type
Research
$227.5M
15,121 transactions
General
$12.2M
48,165 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Pediatric classical hodgkin lymphoma consortium study: chod17 | Seagen Inc. | $28.5M | 0 |
| A Phase 2 Front-Line PET/CT-2 Response-Adapted Brentuximab Vedotin and Nivolumab Incorporated and Radiation Free Management of Early Stage Classical Hodgkin Lymphoma (cHL) | Seagen Inc. | $20.7M | 0 |
| A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) | Seagen Inc. | $16.2M | 0 |
| A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD | Seagen Inc. | $14.5M | 0 |
| A Phase II Study Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone CHEP-BV Followed by BV Consolidation in Patients with CD30-Positive Peripheral T-cell Lymphomas | Seattle Genetics, Inc. | $7.3M | 0 |
| A Phase 2 Study of Brentuximab Vedotin in Combination With Pembrolizumab in Subjects With Metastatic Solid Malignancies After Progression on Prior PD-1 Inhibitor Treatment | Seagen Inc. | $6.7M | 0 |
| A Phase II Trial of PET-Directed Therapy using AVD doxorubicin, vinblastine, and dacarbazine plus Brentuximab Vedotin Induction Chemotherapy Followed by Nivolumab Consolidation for Patients with Previously Untreated Non-bulky Limited Stage Hodgkin Lymphoma | Seattle Genetics, Inc. | $6.4M | 0 |
| A Phase II Trial of PET-Directed Therapy using AVD (doxorubicin, vinblastine, and dacarbazine) plus Brentuximab Vedotin Induction Chemotherapy Followed by Nivolumab Consolidation for Patients with Previously Untreated Non-bulky Limited Stage Hodgkin Lymphoma | Seagen Inc. | $6.1M | 0 |
| PACIFIC: A Phase II Study to Determine the Response Kinetics, Safety and Efficacy of Brentuximab Vedotin and Nivolumab Alone and Combined with Rituximab, Cyclophosphamide, Doxorubicin and Prednisone for Patients with Untreated Primary Mediastinal Large B-Cell Lymphoma | Seagen Inc. | $5.5M | 0 |
| A Pilot Study of Brentuximab Vedotin Combined with AVD Chemotherapy and 30 Gy Involved-Site Radiotherapy in Patients with Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma | Seattle Genetics, Inc. | $5.0M | 0 |
| A Randomized Phase 2 Trial of Brentuximab Vedotin (SGN35, NSC# 749710), or Crizotinib (NSC#749005, Commercially Labeled) in Combination With Chemotherapy for Newly Diagnosed Patients With Anaplastic Large Cell Lymphoma (ALCL) | Seagen Inc. | $5.0M | 0 |
| A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults | Seagen Inc. | $4.5M | 0 |
| Phase II , Multi-center Trial of Nivolumab and Brentuximab Vedotin in Patients with Untreated Hodgkin Lymphoma Over the Age of 60 Years or Unable to Receive Standard ABVD Chemotherapy | Seattle Genetics, Inc. | $4.0M | 0 |
| A Phase II Study Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed by BV Consolidation in Patients with CD30-Positive Peripheral T-cell Lymphomas | Seagen Inc. | $4.0M | 0 |
| SG0350025 | Seattle Genetics, Inc. | $3.7M | 0 |
| A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma HL in Adults Age 60 and Above | Seattle Genetics, Inc. | $3.7M | 0 |
| A Phase 2 study of Brentuximab Vedotin plus Nivolumab without Stem Cell Consolidation in Patients with Relapsed Classical Hodgkin Lymphoma | Seagen Inc. | $3.7M | 0 |
| A Phase I Trial Assessing the Feasibility of Romidepsin Combined with Brentuximab Vedotin for Patients with Requiring Systemic Therapy for Cutaneous T-cell Lymphoma | Seagen Inc. | $3.3M | 0 |
| SG035IST032 | Seattle Genetics, Inc. | $3.0M | 0 |
| A PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN PLUS NIVOLUMAB WITHOUT STEM CELL CONSOLIDATION IN PATIENTS WITH RELAPSED CLASSICAL HODGKIN LYMPHOMA | PFIZER INC. | $2.9M | 0 |
Top Doctors Receiving Payments for ADCETRIS
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Allentown, PA | $228.5M | 15,534 |
| , MD | Medical Oncology | Dallas, TX | $1.2M | 237 |
| Andrew Whiteley | Internal Medicine | Dallas, TX | $1.1M | 212 |
| , MD | Hematology & Oncology | Cleveland, OH | $303,919 | 330 |
| , MD | Hematology | Jackson, MS | $258,226 | 198 |
| , M.D | Hematology & Oncology | New York, NY | $239,971 | 213 |
| , DO, MS | Hematology | Boston, MA | $199,315 | 136 |
| , M.D | Hematology & Oncology | Hershey, PA | $194,974 | 148 |
| , MD | Hematology & Oncology | Washington, DC | $179,289 | 173 |
| , M.D | Hematology & Oncology | Scottsdale, AZ | $171,545 | 176 |
| , M.D | Hematology & Oncology | Salt Lake City, UT | $159,699 | 106 |
| , M.D | Hematology & Oncology | New York, NY | $159,048 | 138 |
| , MD | Hematology | Durham, NC | $158,848 | 107 |
| , M.D | Hematology & Oncology | Los Angeles, CA | $129,636 | 85 |
| , M.D, PHD | Hematology & Oncology | Morristown, NJ | $125,591 | 113 |
| , M.D | Hematology & Oncology | Pittsburgh, PA | $117,673 | 119 |
| , M.D | Hematology & Oncology | Sacramento, CA | $101,581 | 77 |
| , M.D, PH.D | Internal Medicine | Orlando, FL | $101,005 | 76 |
| , M.D | Hematology & Oncology | Sioux Falls, SD | $97,945 | 97 |
| , MD | Medical Oncology | New Brunswick, NJ | $97,780 | 82 |
| , M.D | Specialist | Atlanta, GA | $96,944 | 111 |
| , RN MSN APN | Oncology | Hackensack, NJ | $93,878 | 176 |
| , MD | Medical Oncology | New Haven, CT | $91,858 | 78 |
| , MD | Internal Medicine | Livonia, MI | $89,972 | 63 |
| , MD | Hematology & Oncology | Milwaukee, WI | $87,009 | 93 |
Ad
Manufacturing Companies
- Seagen Inc. $149.2M
- Seattle Genetics, Inc. $75.2M
- PFIZER INC. $13.2M
- Millennium Pharmaceuticals, Inc. $2.1M
- Takeda Pharmaceuticals U.S.A., Inc. $124,461
- Takeda Pharmaceutical Company, Limited $3,300
- PBG PUERTO RICO LLC $193.57
Product Information
- Type Biological
- Total Payments $239.7M
- Total Doctors 11,100
- Transactions 63,286
About ADCETRIS
ADCETRIS is a biological associated with $239.7M in payments to 11,100 healthcare providers, recorded across 63,286 transactions in the CMS Open Payments database. The primary manufacturer is Seagen Inc..
Payment data is available from 2017 to 2024. In 2024, $13.2M was paid across 2,685 transactions to 948 doctors.
The most common payment nature for ADCETRIS is "Unspecified" ($227.5M, 94.9% of total).
ADCETRIS is associated with 20 research studies, including "Pediatric classical hodgkin lymphoma consortium study: chod17" ($28.5M).